BMJ Open Impact of COVID-19 pandemic on haemorrhagic stroke admissions: a systematic review and meta-analysis

Yijie You ¹, ¹ Yunlian Niu,² Fengbing Sun,¹ Jian Zhang,¹ Sheng Huang,¹ Peiyuan Ding,¹ Xuhui Wang³

ABSTRACT

To cite: You Y, Niu Y, Sun F, et al. Impact of COVID-19 pandemic on haemorrhagic stroke admissions: a systematic review and meta-analysis. *BMJ Open* 2021;**11**:e050559. doi:10.1136/ bmjopen-2021-050559

Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2021-050559).

Received 23 February 2021 Accepted 19 November 2021

Check for updates

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Department of Neurosurgery, Shanghai Jiaotong University School of Medicine, Xinhua Hospital Chongming Branch, Shanghai, China ²Department of Neurology, Shanghai Jiaotong University School of Medicine, Xinhua Hospital Chongming Branch, Shanghai, China ³Department of Neurosurgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China

Correspondence to

Dr Yijie You; cematianya@foxmail.com and Mr Peiyuan Ding; 13564338032@163.com **Background and purpose** COVID-19 pandemic, a global health crisis, is disrupting the present medical environment. This systematic review and meta-analysis aimed to evaluate the impact of the COVID-19 pandemic on stroke hospitalisations, especially haemorrhagic stroke. **Methods** The EMBASE, PubMed, Web of Science.

Elsevier, Medline, Cochrane Library and Google Scholar electronic databases were searched for all relevant studies. Two researchers independently screened the studies, extracted data and assessed the quality of the included studies. Odds ratio (OR), total events, OR and 95% Cl were considered as the effect size. A fixed-effects model was used to pool the study-specific estimate. The present study was performed by using Review Manager (V.5.3.0) software. We assessed the risk of bias using the Newcastle–Ottawa Scale.

Results A total of 17 studies with 14 445 cases were included. Overall, the number of stroke admissions is lower in the pandemic period versus the control period (6252 vs 8193). The difference of haemorrhagic stroke is significant, with 1233 of 6252 cases in the pandemic group and 1621 of 8193 cases in the control group. Intracerebral haemorrhage is present in 461 of 1948 cases in the pandemic group and 618 of 2734 cases in the control group. As for subarachnoid haemorrhage, the difference between the two groups is significant, with 70 of 985 cases in the pandemic group.

Conclusions The number of stroke admissions is lower in the pandemic period compared with the control period. There is a higher rate of haemorrhagic stroke in the pandemic period. Subgroup analysis identifies a significant increase in the occurrence of intracerebral haemorrhage in the pandemic period. Due to limited data and the impact of a single article, the impact of COVID-19 pandemic on subarachnoid haemorrhage is unclear.

INTRODUCTION

In December 2019, COVID-19 or SARS-CoV-2 was first reported in Wuhan, China.¹ On 30 January 2020, the WHO declared COVID-19 as a Public Health Emergency of International Concern.² As of 16 August 2021, there have been over 206.69 million confirmed cases and 4 352 488 deaths globally, resulting in serious social and economic implications.³⁴

Strengths and limitations of this study

- Because we collected results from different regions, the meaning of our study is wide and important.
- The result of this study is credible by meta-analysis, which could further explain disputes between different articles.
- This study lacks information about stroke severity and prognoses, which might have to some extent underestimated impacts of the pandemic on stroke.
- The total number of inpatients in the pandemic was not reported, so the prevalence of stroke is inconclusive.
- Although our meta-analysis indicates higher morbidity of intracerebral haemorrhage, the reliability needs to be verified by further researches because of the small sample size.

Stroke is the second leading cause of death and functional inability worldwide, and one of the main contributors of disability-adjusted life years among neurological disorders.^{5 6} The burden of stroke is projected to increase via absolute numbers of incident strokes and deaths.⁷ The main contributor to stroke burden is ischaemic stroke, followed by intracerebral haemorrhage (ICH) and subarachnoid haemorrhage (SAH).78 To prevent and treat stroke, most countries try to establish major and emerging strategies, including activities that reinforce the local healthcare system through the establishment of a social, economic, environmental and cultural combination.910

Unfortunately, the COVID-19 outbreak affected acute stroke services, both direct and indirect. During the pandemic, a lot of people refuse to visit the hospital due to nosocomial infection, and some studies indicate that the incidence of acute conditions such as myocardial infarction and ischaemic stroke has reduced.^{11 12} The World Stroke Organization (WSO) survey showed that the number of acute stroke admissions was reduced in multiple countries, including Chile, Colombia, Iran, Greece, the UK, Belgium and Italy.¹³ In addition, concerns have been raised about the impact of COVID-19 pandemic on haemorrhagic stroke (HS), including ICH and SAH.¹⁴⁻¹⁶ For example, Balestrino *et* al,¹⁷ John *et al*¹⁸ and Schwarz *et al*¹⁹ reported that the HS admission has increased in the pandemic period compared with the control period. However, reports of Rameez *et al*,¹⁶ Zini *et al*²⁰ and Sacco *et* *al* showed that the HS admission was reduced in the pandemic period. It makes the impact remain controversial. Moreover, most of these reports are limited to regional or country-specific analysis, and thus, there is no systematic review and meta-analysis on the impact of the COVID-19 pandemic on the HS admission. To further examine whether this pandemic influenced the HS admission, we reviewed recent studies that compared rates of HS admissions




Figure 1 Flow chart of study selection process.

Table 1	Summary of cl	naracteristics o	Summary of characteristics of included studies	St						
Author	Study design	Region	Age (years)	Male (%)	Pandemic period	Control period	Total number of intracerebral haemorrhage admissions (pandemic vs control)	Total number of subarachnoid haemorrhage admissions (pandemic vs control)	Total number of haemorrhagic stroke admissions (pandemic vs control)	Total number of stroke admissions (pandemic vs control)
Balestrino et al ¹⁷	Single centre; retrospective observational	Italy	N/A	N/A	8 March 2020–2 May 2020	8 March 2019–2 May 2019	N/A	N/A	20 vs 17	124 vs 165
John et al ¹⁸	Single centre; retrospective observational	UAE	48.9 (±14.7) vs 49.3 (±14.1)	66.7 vs 80.8	1 March 2020 –10 May 2020	1 March 2019 –10 May 2019	24 vs 12	13 vs 13	42 vs 26	210 vs 148
Rameez et al ¹⁶	Single centre; retrospective observational	USA	65.6 vs 72.4	61.7 vs 51.3	24 March 2020–23 April 2020	24 March 2019–23 April 2019	9 vs 12	0 vs 0	9 vs 12	47 vs 80
Zini et al ²⁰	Single centre; retrospective observational	Italy	71.7 (±18) vs 75.2 (±13.8)	53.8 vs 50.7	1 March 2020–30 April 2020	1 March 2019–30 April 2019	17 vs 21	N/A	17 vs 21	145 vs 138
Schwarz et al ¹⁹	Single centre; retrospective observational	Germany	N/A	N/A	Calendar weeks 1–16 in 2020	Calendar weeks 1–16 in 2019	32 vs 24	N/A	32 vs 24	286 vs 386
Sarfo et al ²²	Single centre; retrospective observational	Ghana	60.6 (±14.8) vs 59.7 (±15.4)	57.1 vs 53.4	19 January 2020– 20 June 2020	19 January 2019– 20 June 2019	N/A	N/A	118 vs 111	431 vs 401
Sacco et al ¹⁵	Multicentre; prospective and retrospective	Italy	73.5 (±12.9) vs 73.6 (±13.3)	53 vs 53.4	1 March 2020–31 March 2020	1 March 2019–31 March 2019	N/A	N/A	322 vs 400	2379 vs 3145
Roushdy et al ²³	Single centre; retrospective observational	Egypt	63.2 (±12.7) vs 63 (±13.8)	61.3 vs 57	15 February 2020– 5 April 2020	15 February 2019– 5 April 2019	7 vs 5	1 vs 3	8 vs 8	93 vs 151
Altunisik and Arık ²⁶	Single centre; retrospective observational	Turkey	71.95 (±12.37) vs 70.96 (±13.52)	61.36 vs 53.93	1 April 2020–31 May 2020	1 April 2019–31 May 2019	3 vs 8	N/A	3 vs 8	40 vs 72
Luke et al ²⁷	Single centre; retrospective observational	Switzerland	N/A	N/A	11 March 2020–26 May 2020	11 March 2019–26 May 2019	26 vs 19	N/A	26 vs 19	200 vs 223
Thomas <i>et</i> a/ ²⁸	t Multicentre; retrospective observational	Austria	N/A	N/A	1 March 2020–31 May 2020	1 March 2019–31 May 2019	N/A	N/A	188 vs 219	1014 vs 1185
Abdoreza et al ²⁹	Single centre; retrospective observational	Iran	69.21 (±13.88) vs 68.74 (±14.49)	55.17 vs 55.21	18 February 2020– 18 July 2020	18 February 2019– 18 July 2019	48 vs 50	N/A	48 vs 50	229 vs 352
										Continued

6

Table 1	Table 1 Continued									
Author	Study design	Region	Age (years)	Male (%)	Pandemic period	Control period	Total number of intracerebral haemorrhage admissions (pandemic vs control)	Total number of Total number of subarachnoid haemorrhagic haemorrhage stroke admissions admissions (pandemic vs (pandemic vs control) control)	Total number of haemorrhagic stroke admissions (pandemic vs control)	Total number of stroke admissions (pandemic vs control)
Hasan <i>et</i> a/ ³⁰	Single centre; retrospective observational	Bangladesh	N/A	N/A	1 April 2020–30 June 2020	1 January 2020 –31 282 vs 449 March 2020	282 vs 449	52 vs 182	334 vs 631	487 vs 907
Robin <i>et</i> al ²⁴	Single centre; retrospective observational	Germany	77 (64–82) vs 79 47.6 (69–85)	47.6 vs 45.7	16 March 2020–12 16 March 2019–12 April 2020 April 2019		6 vs 6	N/A	6 vs 6	63 vs 70
Ramírez- Moreno et a/ ³¹	Ramírez- Multicentre; Moreno <i>et</i> retrospective a/ ³¹ observational	Spain	70.9 (±2.9)	N/A	1 January 2020–31 May 2020	1 January 2020–31 1 January 2019 –31 N/A May 2020 May 2019	N/A	N/A	44 vs 48	273 vs 451
Timo et al ²⁵	Single centre; retrospective observational	Germany	72.9 (±12.5) vs 72.6 (±13.4)	46.6 vs 54.3	vs 54.3 March/April 2020	March/April 2019	7 vs 12	4 vs 4	9 vs 13	148 vs 207
Gabriel et a/ ³²	Single centre; retrospective observational	Spain	68 (53-79) vs 76 51.8 (60.2-83)	51.8 vs 55.4	14 March 2020-14 14 March 2019-14 May 2020 May 2019	14 March 2019–14 May 2019	N/A	N/A	7 vs 8	83 vs 112
N/A: No data.	ata.									

between corresponding periods of pandemic and pre-pandemic.

MATERIALS AND METHODS

Research strategy and selection criteria

Our systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Two authors (YY and YN) independently identified studies published until 22 August 2021 through systematically searching EMBASE, PubMed, Web of Science, Elsevier, Medline, Cochrane Library and Google Scholar. The following search key terms were used: stroke, subarachnoid hemorrhage, hemorrhagic stroke, cerebral hemorrhage, COVID-19, SARS-CoV-2, pandemic. We used Boolean operators 'AND' or 'OR' to combine the literature searches (online supplemental appendix 1). No language restrictions were applied. Every eligible publication was selected based on the articles' title and abstract by two authors (YY and YN). If there was any disagreement during study screening for relevance, we discussed it with a senior author (PD). This systematic review and meta-analysis was not registered in the International Prospective Register of Systematic Reviews Database.

The inclusion criteria for this review were original articles, retrospective observational studies, prospective and retrospective studies, and research letters. The data of interest were the ICH, SAH, HS and stroke admissions

during the COVID-19 pandemic versus the comparator period. Only studies involving adults were eligible for inclusion. The exclusion criteria included protocols, retracted articles, conference abstracts, preprints, case reports, review articles, biochemical trials, no appropriate outcomes or trials without proper treatment groups and control groups.

Data extraction and quality assessment

The following data were extracted from each article by two independent researchers (YY and YN): author name, publication year, study type and design, source and region of study, patient demographics (age, gender), number of ICH admissions, number of SAH admissions, number of HS admissions and number of stroke admissions. Any conflicts between the researchers were resolved by discussion or decision of a third senior researcher. If there were incomplete data, we attempted to contact the corresponding authors for complete data. We also calculated the necessary information which was not reported in the articles.

The Newcastle–Ottawa Scale was used to evaluate the risk of bias of the included retrospective observational studies. The score consisted of eight items, including adequate case definition, representativeness of cases, selection of controls, definition of controls, comparability, ascertainment of exposure, same method and non-response rate. The total quality score ranged between 0 and 9. Studies assessed with \geq 5 points were regarded

Table 2 Newcastle–Ottawa quality assessment scale and total score of each study									
	New	castle-C)ttawa d	quality a	ssessme	ent scal	е		Score
Included studies	1	2	3	4	5	6	7	8	Total of number of stars
Balestrino et al ¹⁷	В	A*	В	A*	A*	A*	A*	A*	6
John et al ¹⁸	A*	A*	В	A*	A*	A*	A*	A*	7
Rameez et al ¹⁶	В	A*	В	A*	A*	A*	A*	A*	6
Zini <i>et al</i> ²⁰	A*	A*	В	A*	A*	A*	A*	A*	7
Schwarz et al ¹⁹	В	A*	В	A*	A*	A*	A*	A*	6
Sarfo et al ²²	В	A*	В	A*	A*	A*	A*	A*	6
Sacco et al ¹⁵	A*	A*	A*	A*	A**	A*	A*	A*	9
Roushdy et al ²³	В	В	В	A*	A*	A*	A*	A*	5
Altunisik and Arık ²⁶	A*	A*	В	A*	A*	A*	A*	A*	7
Luke et al ²⁷	A*	A*	В	A*	A*	A*	A*	A*	7
Thomas et al ²⁸	A*	A*	A*	A*	A*	A*	A*	A*	8
Abdoreza et al ²⁹	В	A*	В	A*	A*	A*	A*	A*	6
Hasan et al ³⁰	A*	В	A*	A*	В	A*	A*	A*	6
Robin <i>et al²⁴</i>	A*	A*	A*	A*	A*	A*	A*	A*	8
Ramírez-Moreno et al ³¹	A*	A*	В	A*	A*	A*	A*	A*	7
Timo et al ²⁵	A*	A*	A*	A*	A*	A*	A*	A*	8
Gabriel et al ³²	A*	A*	A*	A*	A**	A*	A*	A*	9

A*, one star; A**, two stars; B, no star; 1, adequate case definition; 2, representativeness of cases; 3, selection of controls; 4, definition of controls; 5, comparability; 6, ascertainment of exposure; 7, same method; 8, non-response rate.

as low risk of bias, compared with the studies scoring <5 points that were regarded as high risk of bias.

Data synthesis and analysis

Meta-analysis of proportion was used to determine ICH, SAH, HS and stroke admissions during the pandemic compared with that during the historical pre-pandemic control period. The present study was performed by using Review Manager (V.5.3.0) software. Heterogeneity was calculated by using Q test and I², in which p<0.1, I² >50% meant significant heterogeneity. A fixed-effects model was used when statistically indicated heterogeneity was not found (p>0.1, I² <50%).

Sensitivity analysis was used to assess the impact of individual articles. If there were a limited number of studies (<10), an assessment for publication bias was not performed. Conversely, publication bias was analysed and represented by a funnel plot that allowed evaluation of publication bias by presenting the study's log OR as a function of its SE.

Patient and public involvement

This is a meta-analysis based on study-level data and no individual-level data were involved in the study or in defining the research question or outcome measures.

A	-						
	Pandemic F		Control F			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
Abdoreza et al, 2020	48	229	50	352	3.6%	1.60 [1.03, 2.48]	
Altunisik et al, 2021	3	40	8	72	0.6%	0.65 [0.16, 2.60]	
Balestrino et al, 2020	20	124	17	165	1.4%	1.67 [0.84, 3.35]	<u>+</u>
Gabriel et al, 2021	7	83	8	112	0.7%	1.20 [0.42, 3.44]	
Hasan et al, 2021	334	487	631	907	15.8%	0.95 [0.75, 1.21]	-
John et al, 2020	42	210	26	148	2.8%	1.17 [0.68, 2.02]	
Luke et al, 2021	26	200	19	223	1.8%	1.60 [0.86, 3.00]	<u>+</u>
Rameez et al, 2020	9	47	12	80	0.8%	1.34 [0.52, 3.47]	
Ramírez-Moreno et al, 2021	44	273	48	451	3.5%	1.61 [1.04, 2.50]	
Robin et al, 2021	6	63	6	70	0.6%	1.12 [0.34, 3.68]	
Roushdy et al, 2020	8	93	8	151	0.6%	1.68 [0.61, 4.65]	
Sacco et al, 2020	322	2379	400	3145	34.0%	1.07 [0.92, 1.26]	• •
Sarfo et al, 2020	118	431	111	401	9.5%	0.98 [0.73, 1.34]	+
Schwarz et al, 2020	32	286	24	386	2.1%	1.90 [1.09, 3.30]	
Thomas et al, 2021	188	1014	219	1185	18.8%	1.00 [0.81, 1.25]	+
Timo et al, 2020	9	148	13	207	1.2%	0.97 [0.40, 2.32]	
Zini et al, 2020	17	145	21	138	2.2%	0.74 [0.37, 1.47]	
Total (95% CI)		6252		8193	100.0%	1.10 [1.01, 1.21]	•
Total events	1233		1621				
Heterogeneity: Chi ² = 17.78, d	f= 16 (P = 0.3	(4); $ ^2 = 1$	0%				
Test for overall effect: Z = 2.14							0.01 0.1 1 10 100 Pandemic Period Control Period

В

	Pandemic P	eriod	Control P	eriod		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI
Abdoreza et al, 2020	48	229	50	352	12.0%	1.60 [1.03, 2.48]	
Altunisik et al, 2021	3	40	8	72	2.0%	0.65 [0.16, 2.60]	
Hasan et al, 2021	282	487	449	907	51.0%	1.40 [1.12, 1.75]	■
John et al, 2020	24	210	12	148	4.8%	1.46 [0.71, 3.03]	
Luke et al, 2021	26	200	19	223	6.0%	1.60 [0.86, 3.00]	+
Rameez et al, 2020	9	47	12	80	2.8%	1.34 [0.52, 3.47]	
Robin et al, 2021	6	63	6	70	2.0%	1.12 [0.34, 3.68]	
Roushdy et al, 2020	7	93	5	151	1.4%	2.38 [0.73, 7.72]	
Schwarz et al, 2020	32	286	24	386	7.0%	1.90 [1.09, 3.30]	
Timo et al, 2020	7	148	12	207	3.7%	0.81 [0.31, 2.10]	
Zini et al, 2020	17	145	21	138	7.3%	0.74 [0.37, 1.47]	
Total (95% CI)		1948		2734	100.0%	1.40 [1.19, 1.64]	•
Total events	461		618				
Heterogeneity: Chi ² = 8	3.42, df = 10 (F	e = 0.59)	; I ² = 0%				0.01 0.1 1 10 100
Test for overall effect: 2	Z = 4.14 (P < 0	.0001)					Pandemic Period Control Period

С

0							
	Pandemic F	Period	Control P	eriod		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Hasan et al, 2021	52	487	182	907	85.1%	0.48 [0.34, 0.66]	
John et al, 2020	13	210	13	148	10.7%	0.69 [0.31, 1.52]	
Rameez et al, 2020	0	47	0	80		Not estimable	
Roushdy et al, 2020	1	93	3	151	1.7%	0.54 [0.05, 5.23]	
Timo et al, 2020	4	148	4	207	2.4%	1.41 [0.35, 5.73]	
Total (95% CI)		985		1493	100.0%	0.52 [0.39, 0.70]	•
Total events	70		202				
Heterogeneity: Chi ² = 2	2.67, df = 3 (P	= 0.45);	I ² = 0%				
Test for overall effect: 2	Z = 4.34 (P < 0	0.0001)					Favours (experimental) Favours (control)
							ravours (experimental) ravours (control)

Figure 2 (A) Forest plot showing the HS admission during the pandemic compared with the control period. (B) Forest plot showing the ICH admission during the pandemic compared with the control period. (C) Forest plot showing the SAH admission during the pandemic compared with the control period. HS, haemorrhagic stroke; ICH, intracerebral haemorrhage; SAH, subarachnoid haemorrhage.




Figure 3 Funnel plot with the pooled estimate of the fixed-effects model. (A) The funnel plot of HS group. (B) The funnel plot of ICH group. HS, haemorrhagic stroke; ICH, intracerebral haemorrhage

RESULTS

Study selection

By using the key phrases mentioned above, the literature search yielded 7608 articles from the following databases: 2319 from PubMed, 2079 from EMBASE, 1068 from Web of Science, 463 from Elsevier, 1572 from Medline, 87 from Cochrane Library, 10 from Google Scholar and 10 from other sources. A total of 1775 articles were retained after removal of duplicates. A total of 1708 records were excluded after screening the titles and abstracts, leaving 67 eligible studies. After the full texts were assessed for eligibility, we excluded 50 articles for the following reasons: (1) molecular biology studies (n=5), (2) protocol (n=1), (3) retracted article (n=1), (4) without relevant data (n=43). Finally, 17 studies were eligible and included in our systematic review.^{15–23} A PRISMA diagram detailing the study selection process is shown in figure 1.

Characteristics of included studies

The main characteristics of included studies, including author, the design of study, country or region, age, male to female ratio, pandemic period, control period and each disease admission are summarised in table 1.

A total sample of 14445 subjects from 17 studies was included in the systematic review. The studies were conducted in many countries worldwide including Italy,¹⁵ ¹⁷ ²⁰ United Arab Emirates,¹⁸ the USA,¹⁶ Germany,¹⁹²⁴²⁵ Ghana,²² Turkey,²⁶ Switzerland,²⁷ Austria,²⁸ Iran,²⁹ Bangladesh,³⁰ Spain^{31 32} and Egypt.²³ These studies included retrospective-observational studies and prospective and retrospective studies. All studies were reported on the number of ICH, SAH, HS and stroke admissions during the COVID-19 pandemic compared with the control period.

Risk of bias within studies

The Newcastle–Ottawa score results for each study were shown in table 2. All of these studies were assessed as having a low risk of bias.

Synthesis of results

Haemorrhagic stroke

The HS admission was reported in 17 articles.^{15–20 22–28 30–32} In HS, the pandemic group has 1233 of 6252 cases and the control group has 1621 of 8193 cases. The proportion of HS admissions is higher at stroke admissions in the pandemic period than the proportion of HS admissions in the control period. The difference is significant (OR 1.10, 95% CI 1.01 to 1.21, I²=10%, p=0.03) (figure 2A). Figure 3A shows a funnel plot for the visual inspection of publication bias. The plot shows there is no significant publication bias.

Subgroup analysis

To explore the reason for the increased proportion of HS admissions in the pandemic, we conducted a subgroup analysis based on disease categories. In ICH, the admission was reported in 11 articles.¹⁶ ^{18–20} ^{23–27} ²⁹ ³⁰ It was present in 461 of 1948 cases in the pandemic group and 618 of 2734 cases in the control group, with statistically significant differences between two groups (OR 1.40, 95% CI 1.19 to 1.64, I²=0%, p<0.0001) (figure 2B). The funnel plot shows there is no significant publication bias (figure 3B). In SAH, only five articles showed the SAH admission.¹⁶ ¹⁸ ²³ Seventy of 985 cases in the pandemic group and 202 of 1493 cases in the control group suffered from SAH. The difference is significant (OR 0.52, 95% CI 0.39 to 0.70, I²=0%, p<0.0001) (figure 2C).

Sensitivity analysis

Sensitivity analysis shows that the study of Hasan *et al*^{0} has a significant impact on the outcomes of SAH. As for the outcomes of HS and ICH, there is no individual study that has a significant impact on the outcomes.

DISCUSSION

In this review, the result shows that the number of stroke admissions is reduced in the COVID-19 pandemic. Although the HS admissions are less during the pandemic period than during the pre-pandemic period, the proportion of HS hospitalisations in stroke hospitalisations is significantly increased. Our results further indicate that the number of ICH admissions reduces from 618 in the pandemic group to 461 in the control group, with a corresponding rate raised. As for SAH, the number of SAH admissions and the proportion of SAH admissions are less during the pandemic period than during the control period, but sensitivity analysis indicates that exclusion of an article (Hasan *et al*) influences the pooled estimates.

The WSO survey indicated that the COVID-19 pandemic had a momentous impact on stroke care with delayed presentation and reduced hospital admissions. Our results further support the decreased trend in stroke admissions during the pandemic period by analysing 14445 cases from 17 studies. However, our results on overall strokes might not be comprehensive, because we only considered studies that reported data on HS separately. Although different search strategies are used to weaken the study selection bias, we think that the bias is an objective existence. At all events, the phenomenon of reduced stroke admissions is certain. We find three possible reasons to explain this phenomenon. First, patients who had a stroke and mild symptoms preferred to stay at home and rejected the emergency department for treatment in the pandemic period. Second, increased social isolation decreased the discovery rate of patients who had a stroke, because their friends or family members could not recognise who was suffering from a stroke. Third, under city lockdown, limited transportation made some patients hardly acquire ambulances and drivers, which delayed the treatment for stroke. So we appeal that local government should carry out focused education and intervention for high-risk groups, and provide a green channel for the treatment of strokes. On the other hand, people should strengthen their connection with relatives and friends by phone or online video.

Additionally, we document a numerically higher proportion of HS admissions in stroke admissions and notice that ICH has a significant increase in occurrence during the epidemic. In a previous review and meta-analysis of the risk factors for spontaneous ICH, we identified hypertension and alcohol intake as important risk factors.³³ We further found some studies reported that the pandemic led to an increase in alcohol consumption and alcohol abuse which may be attributed to the stress and isolation experienced with the current pandemic.^{34–44} Therefore, we think that the significant increase of ICH is related to alcohol abuse and stress during the pandemic. But the authenticity needs further validation by special studies. In addition, the data variability is small, because patients with ICH kept seeking hospital care in emergency medical services in the pandemic as they had done in pre-pandemic (eg, the emergency was way heavily avoided that some patients with mild symptoms choose to keep away from hospitals). In summary, in this particular period, the quarantine and social isolation just like some degree of grouping exclude other potentially confounding risk factors. It makes us

have gained a deeper appreciation of obvious risk factors for ICH. In view of the above-mentioned facts, we wish to make the following proposals: (1) people should pay more attention to modifiable risk factors such as alcohol intake and hypertension to reduce the risk of ICH in the COVID-19 pandemic period; (2) various health organisations and clinicians should develop recommendations for people on how to have a healthy lifestyle to cope with physical distancing and social isolation; (3) governments should explore effective prevention and intervention measures to prevent crises. As for SAH, we think it is hard to acquire any important conclusions due to too little data and a huge impact of a single article. It needs more authoritative studies to explore the impact of COVID-19 pandemic on SAH.

Limitations

Limitations to this study are the lack of information about stroke severity and prognoses, which might have to some extent underestimated the impact of the pandemic on stroke. Moreover, the total number of admissions in the pandemic is not reported, so the prevalence of stroke is inconclusive. Although our meta-analysis indicates higher morbidity of HS and ICH, the reliability needs to be verified by further researches because of the small sample size. Despite this, this study still has notable clinical and public health implications. For example, our data may encourage people to conduct further research to prove the potential pathogenesis of ICH. On the other hand, our results could attract more attention to the influence of COVID-19, thus people can perfect isolation approaches and prevention measures.

Conclusions

The study identifies moderate reductions in stroke admissions during the COVID-19 pandemic. Studies have shown that alcohol abuse and stress are important causes of increased ICH hospitalisations during the pandemic. All governments, healthcare institutions, clinicians and academics should aim at preventing potential crisis in the COVID-19 pandemic, exploring more effective policies for prevention and intervention.

Contributors YY conceived and designed the study and drafted the manuscript. YY and YN acquired the data and performed data extraction. YY interpreted the data and performed extensive research on the topic. YY performed the statistical analysis and made all tables and figures. FS, JZ and SH checked the data. PD funded the project. PD and XW supervised the project. YY is the guarantor. All authors contributed to the accomplishment of the manuscript.

Funding The study was supported by the Science and Technology Support Project of Committee of Science and Technology of Chongming District (No. CKY2019-13 to PD).

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval Neither ethics approval nor participant consent was required as this study was based solely on the summary results of previously published articles. Individual patient data were not obtained or accessed.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. The data are available from the corresponding author (cematianya@foxmail.com) upon request.

<u>ð</u>

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Yijie You http://orcid.org/0000-0003-4062-4347

REFERENCES

- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
- 2 Sohrabi C, Alsafi Z, O'Neill N, et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg 2020;76:71–6.
- 3 Lipsitch M, Swerdlow DL, Finelli L. Defining the epidemiology of covid-19 - studies needed. N Engl J Med 2020;382:1194–6.
- 4 World Health Organization. Coronavirus disease (covid-19): weekly epidemiological, update 1, 2020.
- 5 GBD, Stroke, Collaborators. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the global burden of disease study 2016. *Lancet* 2019.
- 6 GBD 2016 Lifetime Risk of Stroke Collaborators, Feigin VL, Nguyen G, et al. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016. N Engl J Med 2018;379:2429–37.
- 7 O'Donnell MJ, Chin SL, Rangarajan S, *et al.* Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. *Lancet* 2016;388:761–75.
- 8 Krishnamurthi RV, Ikeda T, Feigin VL. Global, regional and countryspecific burden of ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage: a systematic analysis of the global burden of disease study 2017. *Neuroepidemiology* 2020;54:171–9.
- 9 Pandian JD, Gall SL, Kate MP, *et al*. Prevention of stroke: a global perspective. *Lancet* 2018;392:1269–78.
- 10 Kimura K. [diagnosis and treatment in acute stroke]. *Rinsho Shinkeigaku* 2010;50:783–6.
- 11 Solomon MD, McNulty EJ, Rana JS, et al. The covid-19 pandemic and the incidence of acute myocardial infarction. N Engl J Med 2020;383:691–3.
- 12 July J, Pranata R. Impact of the coronavirus disease pandemic on the number of strokes and mechanical thrombectomies: a systematic review and meta-analysis. *J Stroke Cerebrovasc Dis* 2020;29:105185.
- 13 Markus HS, Brainin M. COVID-19 and stroke-A global world stroke organization perspective. *Int J Stroke* 2020;15:361–4.
- 14 Wang X, Dong Y, Qi X, et al. Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis. *Stroke* 2013;44:1833–9.
- 15 Sacco S, Ricci S, Ornello R, et al. Reduced admissions for cerebrovascular events during covid-19 outbreak in Italy. Stroke 2020;51:3746–50.
- 16 Rameez F, McCarthy P, Cheng Y, et al. Impact of a stay-at-home order on stroke admission, subtype, and metrics during the covid-19 pandemic. Cerebrovasc Dis Extra 2020;10:159–65.
- 17 Balestrino M, Coccia A, Boffa AS. Request of hospital care dropped for TIA but remained stable for stroke during covid-19 pandemic at a large Italian university hospital. *Intern Emerg Med* 2020:1–5.
- 18 John S, Hussain SI, Piechowski-Jozwiak B, et al. Clinical characteristics and admission patterns of stroke patients during the COVID 19 pandemic: a single center retrospective, observational study from the abu dhabi, United Arab Emirates. *Clin Neurol Neurosurg* 2020;199:106227.
- 19 Schwarz V, Mahfoud F, Lauder L, et al. Decline of emergency admissions for cardiovascular and cerebrovascular events after the outbreak of COVID-19. *Clin Res Cardiol* 2020;109:1500–6.

- 20 Zini A, Romoli M, Gentile M, et al. The stroke mothership model survived during COVID-19 era: an observational single-center study in Emilia-Romagna, Italy. *Neurol Sci* 2020;41:3395–9.
- 21 Luostarinen T, Virta J, Satopää J, et al. Intensive care of traumatic brain injury and aneurysmal subarachnoid hemorrhage in Helsinki during the Covid-19 pandemic. Acta Neurochir 2020;162:2715–24.
- 22 Sarfo FS, Mensah NO, Opoku FA, et al. COVID-19 and stroke: experience in a Ghanaian healthcare system. *J Neurol Sci* 2020;416:117044.
- 23 Roushdy TM, Nahas NME, Aref HM, et al. Stroke in the time of coronavirus disease 2019: experience of two university stroke centers in Egypt. J Stroke 2020;22:275–7.
- 24 Jansen R, Lee J-I, Turowski B, et al. Consequences of COVID-19 pandemic lockdown on emergency and stroke care in a German tertiary stroke center. *Neurol Res Pract* 2021;3.
- 25 Uphaus T, Gröschel S, Hayani E, *et al.* Stroke care within the COVID-19 pandemic-increasing awareness of transient and mild stroke symptoms needed. *Front Neurol*;11.
- 26 Altunişik E, Arık A. Decreased stroke applications during pandemic: collateral effects of covid-19. *Turkish J Neurology/Turk Noroloji Dergisi* 2021;27.
- 27 Carson L, Kui C, Smith G, *et al.* The effect of the 2019 novel coronavirus pandemic on stroke and TIA patient admissions: perspectives and risk factors. *J Clin Med* 2021;10:1357.
- 28 Gattringer T, Fandler-Höfler S, Kneihsl M, et al. Hospital admissions of acute cerebrovascular diseases during and after the first wave of the COVID-19 pandemic: a state-wide experience from Austria. J Neurol 2021;268:3584–8.
- 29 Ghoreishi A, Arsang-Jang S, Sabaa-Ayoun Z, et al. Stroke care trends during covid-19 pandemic in zanjan Province, Iran. from the cascade initiative: statistical analysis plan and preliminary results. J Stroke Cerebrovasc Dis 2020;29:105321.
- 30 Hasan ATMH, Das SC, Islam MS, et al. Impact of COVID-19 on hospital admission of acute stroke patients in Bangladesh. PLoS One;16:e0240385.
- 31 Ramírez-Moreno JA-O, Portilla-Cuenca JC, Hariramani-Ramchandani R, *et al.* Slump in hospital admissions for stroke, a fact of an uncertain nature that requires explanation. lid.
- 32 Velilla-Alonso G, García-Pastor A, Rodríguez-López Ángela, et al. Acute stroke care during the covid-19 pandemic: reduction in the number of admissions of elderly patients and increase in prehospital delays. Cerebrovasc Dis 2021;50:310–6.
- 33 Ariesen MJ, Claus SP, Rinkel GJE, et al. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke 2003;34:2060–5.
- 34 Ćosić K, Popović S, Šarlija M, et al. Impact of human disasters and covid-19 pandemic on mental health: potential of digital psychiatry. *Psychiatr Danub* 2020;32:25–31.
- 35 Sun Y, Li Y, Bao Y, *et al*. Brief report: increased addictive Internet and substance use behavior during the covid-19 pandemic in China. *Am J Addict* 2020;29:268–70.
- 36 Colbert S, Wilkinson C, Thornton L, *et al.* COVID-19 and alcohol in Australia: industry changes and public health impacts. *Drug Alcohol Rev* 2020;39:435–40.
- 37 Kmiec J. President's message: the impact of the COVID-19 public health emergency on the practice of addiction medicine. J Addict Dis 2020;38:235–6.
- 38 Andrade C. COVID-19 and lockdown: delayed effects on health. Indian J Psychiatry 2020;62:247–9.
- 39 Rehm J, Kilian C, Ferreira-Borges C, *et al.* Alcohol use in times of the COVID 19: implications for monitoring and policy. *Drug Alcohol Rev* 2020;39:301–4.
- 40 Carrico AW, Horvath KJ, Grov C, *et al*. Double jeopardy: methamphetamine use and HIV as risk factors for covid-19. *AIDS Behav* 2020;24:3020–3.
- 41 Clay JM, Parker MO. Alcohol use and misuse during the COVID-19 pandemic: a potential public health crisis? *Lancet Public Health*. 2020;5:e259.
- 42 Shigemura J, Ursano RJ, Morganstein JC, et al. Public responses to the novel 2019 coronavirus (2019-nCoV) in Japan: mental health consequences and target populations. *Psychiatry Clin Neurosci* 2020;74:281–2.
- 43 Wang Y, Di Y, Ye J, et al. Study on the public psychological states and its related factors during the outbreak of coronavirus disease 2019 (COVID-19) in some regions of China. *Psychol Health Med* 2021;26:13–22.
- 44 Ramalho R. Alcohol consumption and alcohol-related problems during the COVID-19 pandemic: a narrative review. *Australas Psychiatry* 2020;28:524–6.